Plus Therapeutics, Inc. (PSTV)

Market Cap	11.20M
Revenue (ttm)	5.82M
Net Income (ttm)	-12.98M
Shares Out	17.00M
EPS (ttm)	-2.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	533,411
Open	0.6500
Previous Close	0.6717
Day's Range	0.6220 - 0.6607
52-Week Range	0.2400 - 2.6700
Beta	0.67
Analysts	Strong Buy
Price Target	11.17 (+1,596.02%)
Earnings Date	May 14, 2025

About PSTV

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic drug candidate is REYOBIQ, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 21
• Stock Exchange: NASDAQ
• Ticker Symbol: PSTV
• Website: https://plustherapeutics.com

Financial Performance

In 2024, Plus Therapeutics's revenue was $5.82 million, an increase of 18.54% compared to the previous year's $4.91 million. Losses were -$12.98 million, -2.54% less than in 2023.

Analyst Forecast

According to 3 analysts, the average rating for PSTV stock is "Strong Buy." The 12-month stock price forecast is $11.17, which is an increase of 1,596.02% from the latest price.

Price Target

$11.17

(1,596.02% upside)

Analyst Consensus: Strong Buy